Avalo Therapeutics, Inc. (AVTX) Financials

AVTX Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 29.3 million 14.6 million
2023-06-30 24.2 million 31.2 million
2023-03-31 36.2 million 42.5 million
2022-12-31 33.4 million 44.3 million

AVTX Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -6.8 million 953000
2023-06-30 -10.9 million 893000
2023-03-31 -10.2 million 855000
2022-12-31 -4.0 million 843000

AVTX Net Income

No data available :(

AVTX Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 10.2 million - 536000
2023-06-30 6.3 million - 535000
2023-03-31 16.7 million 10.5 million 533000
2022-12-31 13.2 million - 532000

AVTX Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 46.8 million
2023-06-30 14.0 million
2023-03-31 11.7 million
2022-12-31 9.4 million

AVTX Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 - 1.2 million 2.5 million 7000
2023-06-30 158000 4.7 million 2.4 million 7000
2023-03-31 158000 6.0 million 2.7 million 13000
2022-12-31 56000 6.2 million 2.9 million 12000

AVTX Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 236000 247000
2023-06-30 643000 708000
2023-03-31 475000 551000
2022-12-31 896000 620000

AVTX

Price: $16

52 week price:
3.95
1130.40

Earnings Per Share: -480.00 USD

P/E Ratio: -0.01

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Volume: 45800

Market Capitalization: 12.6 million

Links: